The US Food and Drug Administration (FDA) has awarded breakthrough therapy designation to uniQure's AMT-130 for treating ...

The number of people who have the gene that causes Huntington's disease in Northern Scotland has been accurately counted for ...

How an unlikely source—the medical soap opera "General Hospital"—inspired me to face my genetic fate and get tested for ...

Qure's long-term success hinges on overcoming regulatory and logistical challenges. See why I rate QURE stock a hold.

The number of people living in the area who have the gene that causes the condition has been accurately counted for the first ...

AMT-130 is administered through magnetic resonance imaging-guided, convection-enhanced stereotactic neurosurgical delivery into the striatum.

"Pridopidine shows long-term sustained efficacy up to 2 years, and there's significant long-term benefit confirmed compared ...

Factors driving the market include rising disease prevalence, innovative therapies, and gene-based treatment breakthroughs. Key players like H Lundbeck and Pfizer are fueling research and development ...

The original PROOF-HD trial of pridopidine was negative, but a new analysis showed it has clinically meaningful effects in ...

Get Instant Summarized Text (Gist) The number of individuals carrying the Huntington's disease gene in Northern Scotland has been accurately determined for the first time in 35 years, revealing ...